Hikma intros cefazolin for injection

Hikma is introducing cefazolin for injection in dosage strengths of 2 g and 3 g.

The drug treats certain infections caused by bacteria including skin, bone, joint, genital, blood, the lining of heart chambers and heart valves, respiratory tract, biliary tract and urinary tract infections, and for perioperative prophylaxis.

[Read more: Hikma to acquire Custopharm]

“Hikma is introducing the first 3 gram presentation to the U.S. market and we are pleased to expand our portfolio with this launch, broadening the choice of medicines available to hospitals,” the company said.

[Read more: Hikma to launch 4 generics in Canada]